Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005.
作者信息
Furst D E, Breedveld F C, Kalden J R, Smolen J S, Burmester G R, Bijlsma J W J, Dougados M, Emery P, Keystone E C, Klareskog L, Mease P J
机构信息
1000 Veteran Avenue Rehabilitation Centre, Room 32-59, Los Angeles, CA 90024, USA.
出版信息
Ann Rheum Dis. 2005 Nov;64 Suppl 4(Suppl 4):iv2-14. doi: 10.1136/ard.2005.044941.
Abstract
摘要
相似文献
1
Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005.
Ann Rheum Dis. 2005 Nov;64 Suppl 4(Suppl 4):iv2-14. doi: 10.1136/ard.2005.044941.
2
Updated consensus statement on biological agents, specifically tumour necrosis factor alpha (TNFalpha) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004.
Ann Rheum Dis. 2004 Nov;63 Suppl 2(Suppl 2):ii2-ii12. doi: 10.1136/ard.2004.029272.
3
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006.
Ann Rheum Dis. 2006 Nov;65 Suppl 3(Suppl 3):iii2-15. doi: 10.1136/ard.2006.061937.
4
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011.
Ann Rheum Dis. 2012 Apr;71 Suppl 2:i2-45. doi: 10.1136/annrheumdis-2011-201036.
5
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007.
Ann Rheum Dis. 2007 Nov;66 Suppl 3(Suppl 3):iii2-22. doi: 10.1136/ard.2007.081430.
6
Updated consensus statement on tumour necrosis factor blocking agents for the treatment of rheumatoid arthritis and other rheumatic diseases (April 2001).
Ann Rheum Dis. 2001 Nov;60 Suppl 3(Suppl 3):iii2-5. doi: 10.1136/ard.60.90003.iii2.
7
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008.
Ann Rheum Dis. 2008 Dec;67 Suppl 3:iii2-25. doi: 10.1136/ard.2008.100834.
8
The use of anti-tumour necrosis factor therapy in HIV-positive individuals with rheumatic disease.
Ann Rheum Dis. 2008 May;67(5):710-2. doi: 10.1136/ard.2007.081513. Epub 2007 Dec 13.
9
[Current therapy with TNFalpha blocking agents for ankylosing spondylitis and undifferentiated spondyloarthritis].
Z Rheumatol. 2004 Jun;63(3):203-10. doi: 10.1007/s00393-004-0630-3.
10
[Therapeutic use of "biologics" in inflammatory joint and spinal diseases].
Ther Umsch. 2002 Oct;59(10):535-43. doi: 10.1024/0040-5930.59.10.535.
引用本文的文献
1
Cost-utility analysis of treatment options after initial tumor necrosis factor inhibitor therapy discontinuation in patients with rheumatoid arthritis.
J Manag Care Spec Pharm. 2021 Jan;27(1):73-83. doi: 10.18553/jmcp.2021.27.1.073.
2
Association between C-reactive protein gene variant and treatment efficacy of etanercept in ankylosing spondylitis patients receiving hip arthroplasty.
J Clin Lab Anal. 2020 Aug;34(8):e23343. doi: 10.1002/jcla.23343. Epub 2020 Apr 20.
3
Analysis of gene expression profiles and protein-protein interaction networks in multiple tissues of systemic sclerosis.
BMC Med Genomics. 2019 Dec 27;12(1):199. doi: 10.1186/s12920-019-0632-2.
4
β-Endorphin attenuates collagen-induced arthritis partially by inhibiting peripheral pro-inflammatory mediators.
Exp Ther Med. 2018 Apr;15(4):4014-4018. doi: 10.3892/etm.2018.5914. Epub 2018 Feb 28.
5
The association of NLRP3 and TNFRSF1A polymorphisms with risk of ankylosing spondylitis and treatment efficacy of etanercept.
J Clin Lab Anal. 2017 Nov;31(6). doi: 10.1002/jcla.22138. Epub 2017 Jan 23.
6
Biologic therapy for refractory scleritis: a new treatment perspective.
Int Ophthalmol. 2015 Dec;35(6):903-12. doi: 10.1007/s10792-015-0124-0. Epub 2015 Aug 29.
7
A prospective, randomized, double-blind, multicentre, parallel-group, active controlled study to compare efficacy and safety of biosimilar adalimumab (Exemptia; ZRC-3197) and adalimumab (Humira) in patients with rheumatoid arthritis.
Int J Rheum Dis. 2016 Nov;19(11):1157-1168. doi: 10.1111/1756-185X.12711. Epub 2015 Jul 14.
8
Psoriasis, anti-tumor necrosis factor therapy, and tuberculosis: report of three challenging cases and literature review.
Infect Dis Ther. 2013 Jun;2(1):59-73. doi: 10.1007/s40121-013-0003-9. Epub 2013 Feb 15.
9
Abatacept for the treatment of rheumatoid arthritis: A review.
Curr Ther Res Clin Exp. 2007 Nov;68(6):379-99. doi: 10.1016/j.curtheres.2007.12.001.
10
Temporal cytokine expression and the target organ attributes unravel novel aspects of autoimmune arthritis.
Indian J Med Res. 2013 Nov;138(5):717-31.
本文引用的文献
1
The comparative effectiveness of tumor necrosis factor-blocking agents in patients with rheumatoid arthritis and patients with ankylosing spondylitis: a six-month, longitudinal, observational, multicenter study.
Arthritis Rheum. 2005 Aug;52(8):2506-12. doi: 10.1002/art.21209.
2
Adalimumab: a review of side effects.
Expert Opin Drug Saf. 2005 Jul;4(4):637-41. doi: 10.1517/14740338.4.4.637.
3
Impact of managed care on the use of biologic agents for rheumatoid arthritis.
Arthritis Rheum. 2005 Jun 15;53(3):423-30. doi: 10.1002/art.21178.
4
Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab.
Arthritis Res Ther. 2005;7(3):R439-44. doi: 10.1186/ar1693. Epub 2005 Feb 21.
5
Infliximab treatment for refractory Kawasaki syndrome.
J Pediatr. 2005 May;146(5):662-7. doi: 10.1016/j.jpeds.2004.12.022.
6
Reactivation of a latent precore mutant hepatitis B virus related chronic hepatitis during infliximab treatment for severe spondyloarthropathy.
Ann Rheum Dis. 2005 May;64(5):788-9. doi: 10.1136/ard.2004.031187.
7
Interleukin-1 blockade by anakinra improves clinical symptoms in patients with neonatal-onset multisystem inflammatory disease.
Arthritis Rheum. 2005 Apr;52(4):1283-6. doi: 10.1002/art.20953.
8
Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT).
Arthritis Rheum. 2005 Apr;52(4):1227-36. doi: 10.1002/art.20967.
9
Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study.
Arthritis Rheum. 2005 Apr;52(4):1020-30. doi: 10.1002/art.20982.
10
Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study.
J Hepatol. 2005 Mar;42(3):315-22. doi: 10.1016/j.jhep.2004.11.025.
Zotero 插件